P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL

• Daniel Lopes De Menezes,
• Andrew Wei,
• Hartmut Döhner,
• Gail Roboz,
• Maria Teresa Voso,
• Andre Schuh,
• Wendy L. See,
• Manuel Ugidos,
• Arnaud Amzallag,
• Alberto Risueño,
• Charalampos Kyriakopoulos,
• Rajasekhar Nvs Suragani,
• Barry Skikne,
• CL Beach,
• Thomas Prebet,
• Anita Gandhi

Affiliations

Daniel Lopes De Menezes

1 Bristol Myers Squibb, San Francisco, CA, United States

Andrew Wei

2 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia

Hartmut Döhner

3 Ulm University Hospital, Ulm, Germany

Gail Roboz

4 Weill Cornell Medicine, New York, NY, United States

Maria Teresa Voso

5 University of Rome Tor Vergata, Rome, Italy

Andre Schuh

6 Princess Margaret Cancer Centre, Toronto, Canada

Wendy L. See

1 Bristol Myers Squibb, San Francisco, CA, United States

Manuel Ugidos

7 BMS Center for Innovation and Translational Research Europe (CITRE, a Bristol-Myers Squibb Company), Seville, Spain

Arnaud Amzallag

8 Bristol Myers Squibb, Cambridge, MA, United States

Alberto Risueño

9 Bristol Myers Squibb, Lawrenceville, NJ, United States

Charalampos Kyriakopoulos

7 BMS Center for Innovation and Translational Research Europe (CITRE, a Bristol-Myers Squibb Company), Seville, Spain

Rajasekhar Nvs Suragani

8 Bristol Myers Squibb, Cambridge, MA, United States

Barry Skikne

10 University of Kansas Cancer Center, Kansas City, KS, United States

CL Beach

12 Bristol Myers Squibb, Summit, NJ, United States

Thomas Prebet

12 Bristol Myers Squibb, Summit, NJ, United States

Anita Gandhi

12 Bristol Myers Squibb, Summit, NJ, United States